NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

Sponsor: University of Iowa
Collaborator: V Foundation

Purpose

Determine whether Nicotinamide riboside can ameliorate persistent peripheral neuropathy in cancer survivors who have completed chemotherapy with taxane or platinum-complex compounds between 1 and 12 months earlier.

Study Design

Randomized, double blind, placebo controlled, parallel assignment

Dose

2x 250mg NR in the a.m. and 2x 250mg NR in the p.m. daily

Length of Intervention

84 days

Intrinsic Capacity

Sensory

Status

Recruiting

Condition or Disease 

Chemotherapy-induced Peripheral Neuropathy

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Clinical Studies, Sensory, RecruitingANAD Staff